Therapy Area topics
Cardiovascular
Fibrogen stretches the bounds of credibility
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Central Nervous System
Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Diabetes
Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Digital Health
Cognito’s Alzheimer’s brainwave
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Oncology
A surprise Keytruda approval, and what it means for biotech
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
Respiratory
Vertex’s second try at a rare lung disorder
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Various
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
